EDAP Announces Completion Of Enrollment In Phase 3 Study Evaluating Focal One HIFU Therapy For Deep Infiltrating Rectal Endometriosis
Portfolio Pulse from Benzinga Newsdesk
EDAP has completed enrollment for its Phase 3 study of Focal One HIFU therapy for deep infiltrating rectal endometriosis, with 60 patients enrolled in under 9 months. Study results are anticipated in the second half of 2024.
February 01, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EDAP completes Phase 3 enrollment for its Focal One HIFU therapy for rectal endometriosis, with results expected in the second half of 2024.
Completing enrollment for a Phase 3 study is a significant milestone for EDAP, indicating progress in its product pipeline. Positive study results could lead to increased investor confidence and potential revenue growth from the new therapy, thus likely to positively impact EDAP's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100